Abstract

Changing definitions and classifications of hematologic malignancies (HMs) complicate incidence comparisons. HAEMACARE classified HMs into groupings consistent with the latest World Health Organization classification and useful for epidemiologic and public health purposes. We present crude, age-specific and age-standardized incidence rates for European HMs according to these groupings, estimated from 66 371 lymphoid malignancies (LMs) and 21 796 myeloid malignancies (MMs) registered in 2000-2002 by 44 European cancer registries, grouped into 5 regions. Age-standardized incidence rates were 24.5 (per 100 000) for LMs and 7.55 for MMs. The commonest LMs were plasma cell neoplasms (4.62), small B-cell lymphocytic lymphoma/chronic lymphatic leukemia (3.79), diffuse B-cell lymphoma (3.13), and Hodgkin lymphoma (2.41). The commonest MMs were acute myeloid leukemia (2.96), other myeloproliferative neoplasms (1.76), and myelodysplastic syndrome (1.24). Unknown morphology LMs were commonest in Northern Europe (7.53); unknown morphology MMs were commonest in Southern Europe (0.73). Overall incidence was lowest in Eastern Europe and lower in women than in men. For most LMs, incidence was highest in Southern Europe; for MMs incidence was highest in the United Kingdom and Ireland. Differences in diagnostic and registration criteria are an important cause of incidence variation; however, different distribution of HM risk factors also contributes. The quality of population-based HM data needs further improvement.

Introduction

Hematologic malignancies (HMs) are a heterogeneous group of diseases of diverse incidence, prognosis, and etiology. Most population-based studies on the incidence of HMs have grouped these diseases into broad categories: Hodgkin versus non-Hodgkin lymphoma, acute versus chronic, and lymphatic versus myeloid leukemia.1,2 

Comparison of HM incidence across regions and over time is complicated by the existence of different disease classification systems and by the fact that the criteria for disease definition vary between countries, and even between treatment centers and cancer registries (CRs) within a country.3  The situation is further complicated by the major changes in HM classification that have occurred in recent years. The most recent HM classifications, the third revision of the International Classification of Diseases-Oncology (ICD-O-3) published in 20004  and the closely related World Health Organization (WHO) publications5,6  classify HMs at the most basic level according to cell lineage and cell maturity but use morphologic, genotypic, genetic, and immunohistochemical criteria, as well as clinical behavior, to further subdivide these entities. The ICD-O-3 classification is thought to have been applied retrospectively by most European CRs to their HM incident data from the year 2000.

HAEMACARE is a European CR-based project funded by the European Commission and set up in 2005 to improve the standardization and availability of population-based data on HMs archived by EUROCARE CRs.7,8  Under the aegis of HAEMACARE, hematologists, pathologists, and epidemiologists from several European countries reached a consensus on the grouping of lymphoid and myeloid neoplasms (as defined by ICD-O-3 morphology codes and WHO recommendations) into categories based primarily on cell lineage but with subcategories based on similar prognosis and therefore useful for epidemiologic and public health purposes. The HAEMACARE grouping system thus produced incorporates the latest changes introduced by the WHO classification6  and is consistent with the classification of lymphoid neoplasms for epidemiologic research proposed by the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) in 2007.9 

The aim of this study is to present and analyze data on HM incidence from European CRs, classified according to ICD-O-3 morphology codes, and grouped according to HAEMACARE indications. To ensure analysis of a relatively homogeneous set of cases, only cases incident from 2000-2002 were considered.

Methods

Cancer registries

The present EUROCARE network includes most, but not all, European CRs and covers approximately 30% of the European population. All EUROCARE CRs were invited to participate in the present HAEMACARE study, but only 48 CRs, operating in 20 countries,8  had incidence data for at least one of the predefined study years (2000-2002). Eleven of the CRs participating in the present study cover populations of entire countries; the other CRs cover variable percentages of national populations. The CRs were grouped into 5 geographic regions: Northern Europe (Iceland, Norway, and Sweden); United Kingdom and Ireland (England, Ireland, Northern Ireland, Scotland, and Wales); Central Europe (Austria, France, Germany, Switzerland, and The Netherlands); Southern Europe (Italy, Malta, Slovenia, and Spain); and Eastern Europe (Czech Republic, Poland, and Slovakia).

The proportion of national coverage and number of cases contributed by each CR, with age at diagnosis, are shown in Table 1, together with indicators of data quality. Thirty-nine CRs provided incidence data for 2000-2002, 5 for 2000-2001, and 4 for 2000, for a total of 97 521 incident cases.

Table 1

Percentage of national coverage, coverage period, reference population, number of cases, mean and median age at diagnosis, and data quality indicators for 48 European CRs with incidence data in 2000-2002 for hematologic malignancies

European region/country Cancer registry National coverage,* percentage Cases diagnosed in 2000-2002
 
Years covered Average population per year Total cases Mean age, y Median age, y Death certificate only/autopsy, percentage Verified microscopically, percentage Unknown morphology,† percentage 
Northern Europe     16 837 65 70 1.5 99.0 25.3 
    Iceland Iceland 100.0 2000-2002 282 995 243 61 67 0.4 100.0 0.8 
    Norway Norway 100.0 2000-2002 4 502 000 5229 65 69 1.0 97.0 16.6 
    Sweden Sweden 100.0 2000-2002 8 884 449 11 365 66 70 1.7 99.9 29.8 
United Kingdom and Ireland     39 575 65 69 2.9 90.2 15.2 
    Ireland Ireland 100.0 2000-2002 3 836 871 4303 62 67 2.8 95.7 21.0 
    England United Kingdom East Anglia 5.4 2000-2002 2 749 513 3972 66 70 1.4 95.1 16.2 
United Kingdom Northern and Yorkshire 13.3 2000-2002 6 563 034 8962 66 70 1.1 95.8 14.0 
United Kingdom Oxford 5.4 2000-2002 2 732 200 2897 63 67 0.5 100.0 16.1 
United Kingdom West Midlands 10.7 2000-2002 5 284 832 6281 65 69 6.4 84.0 12.5 
    Northern Ireland United Kingdom Northern Ireland 100.0 2000-2002 1 689 635 1694 63 67 1.3 76.1 29.7 
    Scotland United Kingdom Scotland 100.0 2000-2002 5 060 647 7623 66 70 0.5 95.5 11.1 
    Wales United Kingdom Wales 100.0 2000-2002 2 913 498 3843 66 70 10.8 64.3 15.9 
Central Europe     16 587 63 68 5.2 93.2 17.0 
    Austria‡ Austria 100.0 2000-2002 8 029 426 6998 64 69 10.3 86.8 32.3 
    France Cote d'Or (Cancer Registry of Haematological Malignancies) 0.9 2000-2002 508 222 741 66 71 0.0 100.0 3.5 
    Germany Saarland 1.3 2000-2002 1 067 443 1269 64 67 4.5 91.0 7.1 
    Switzerland Basel 6.1 2000-2001 433 027 278 64 68 3.2 99.6 5.8 
Geneva 5.6 2000-2002 417 096 532 64 68 0.6 98.1 17.3 
St Gallen 7.2 2000-2002 519 583 621 63 68 1.3 100.0 6.3 
Ticino 4.3 2000-2002 311 549 413 63 67 2.7 94.9 6.5 
    The Netherlands Amsterdam 17.6 2000-2002 2 872 613 2685 61 65 0.6 99.1 2.9 
Eindhoven 6.1 2000-2001 989 680 581 60 64 0.0 97.9 8.5 
North Netherlands 12.9 2000-2001 2 070 146 1380 62 66 2.3 98.5 5.4 
Twente 7.2 2000-2002 1 156 162 1089 62 67 0.7 99.0 5.6 
Southern Europe     17 972 64 68 1.1 92.4 17.4 
    Italy Alto Adige 0.8 2000-2002 465 938 504 64 68 0.0 99.0 5.0 
Biella 0.3 2000-2002 187 983 370 66 70 0.3 95.7 3.2 
Ferrara 0.6 2000-2002 347 156 611 67 71 0.8 98.7 7.9 
Firenze 2.0 2000-2002 1 162 973 1941 64 68 0.6 69.0 21.5 
Friuli Venezia Giulia 2.1 2000-2002 1 192 711 1918 65 69 1.6 99.6 29.1 
Genova 1.6 2000 900 735 579 67 70 0.9 79.3 7.8 
Modena 1.1 2000-2002 638 743 1045 63 68 0.3 99.4 2.6 
Napoli 0.9 2000 546 399 192 51 57 1.0 76.6 23.6 
Parma 0.7 2000-2002 402 788 769 66 70 0.0 100.0 15.9 
Ragusa 0.5 2000-2002 295 496 453 64 69 1.6 95.4 4.9 
Reggio Emilia‡ 0.8 2000-2002 462 469 734 65 69 0.1 97.3 50.7 
Romagna 1.7 2000-2002 991 045 1713 66 70 2.3 97.5 11.7 
Salerno 1.9 2000-2001 1 082 710 700 61 66 2.7 93.4 22.7 
Sassari 0.8 2000-2002 469 200 576 62 66 0.3 96.7 5.6 
Torino 1.6 2000-2001 900 408 887 64 67 1.0 95.4 22.0 
Trento 0.8 2000 477 859 200 66 70 0.5 96.5 9.0 
Umbria‡ 1.5 2000-2002 833 506 1125 64 69 0.7 77.6 38.8 
Veneto 3.5 2000 2 015 290 944 64 68 1.9 92.6 14.5 
    Malta Malta 100.0 2000-2002 388 752 378 60 65 0.0 98.4 17.5 
    Slovenia Slovenia 100.0 2000-2002 1 990 625 1652 60 66 0.9 100.0 8.8 
    Spain Girona 1.3 2000-2002 558 649 681 64 70 3.4 95.5 5.7 
Eastern Europe     6550 60 65 9.8 91.4 14.5 
    Czech Republic West Bohemia 8.3 2000-2002 854 583 839 61 65 7.0 91.9 12.8 
    Poland Cracow‡ 1.9 2000-2002 731 162 497 60 65 8.5 82.9 34.2 
Kielce 3.1 2000-2002 1 325 260 972 60 66 0.0 89.2 23.5 
Warsaw 4.2 2000-2002 1 673 830 1130 61 66 0.0 97.2 13.6 
    Slovakia Slovakia 100.0 2000-2002 5 385 464 3112 58 64 17.3 91.2 9.3 
Total     97 521 64 69 3.2 92.7 17.6 
European region/country Cancer registry National coverage,* percentage Cases diagnosed in 2000-2002
 
Years covered Average population per year Total cases Mean age, y Median age, y Death certificate only/autopsy, percentage Verified microscopically, percentage Unknown morphology,† percentage 
Northern Europe     16 837 65 70 1.5 99.0 25.3 
    Iceland Iceland 100.0 2000-2002 282 995 243 61 67 0.4 100.0 0.8 
    Norway Norway 100.0 2000-2002 4 502 000 5229 65 69 1.0 97.0 16.6 
    Sweden Sweden 100.0 2000-2002 8 884 449 11 365 66 70 1.7 99.9 29.8 
United Kingdom and Ireland     39 575 65 69 2.9 90.2 15.2 
    Ireland Ireland 100.0 2000-2002 3 836 871 4303 62 67 2.8 95.7 21.0 
    England United Kingdom East Anglia 5.4 2000-2002 2 749 513 3972 66 70 1.4 95.1 16.2 
United Kingdom Northern and Yorkshire 13.3 2000-2002 6 563 034 8962 66 70 1.1 95.8 14.0 
United Kingdom Oxford 5.4 2000-2002 2 732 200 2897 63 67 0.5 100.0 16.1 
United Kingdom West Midlands 10.7 2000-2002 5 284 832 6281 65 69 6.4 84.0 12.5 
    Northern Ireland United Kingdom Northern Ireland 100.0 2000-2002 1 689 635 1694 63 67 1.3 76.1 29.7 
    Scotland United Kingdom Scotland 100.0 2000-2002 5 060 647 7623 66 70 0.5 95.5 11.1 
    Wales United Kingdom Wales 100.0 2000-2002 2 913 498 3843 66 70 10.8 64.3 15.9 
Central Europe     16 587 63 68 5.2 93.2 17.0 
    Austria‡ Austria 100.0 2000-2002 8 029 426 6998 64 69 10.3 86.8 32.3 
    France Cote d'Or (Cancer Registry of Haematological Malignancies) 0.9 2000-2002 508 222 741 66 71 0.0 100.0 3.5 
    Germany Saarland 1.3 2000-2002 1 067 443 1269 64 67 4.5 91.0 7.1 
    Switzerland Basel 6.1 2000-2001 433 027 278 64 68 3.2 99.6 5.8 
Geneva 5.6 2000-2002 417 096 532 64 68 0.6 98.1 17.3 
St Gallen 7.2 2000-2002 519 583 621 63 68 1.3 100.0 6.3 
Ticino 4.3 2000-2002 311 549 413 63 67 2.7 94.9 6.5 
    The Netherlands Amsterdam 17.6 2000-2002 2 872 613 2685 61 65 0.6 99.1 2.9 
Eindhoven 6.1 2000-2001 989 680 581 60 64 0.0 97.9 8.5 
North Netherlands 12.9 2000-2001 2 070 146 1380 62 66 2.3 98.5 5.4 
Twente 7.2 2000-2002 1 156 162 1089 62 67 0.7 99.0 5.6 
Southern Europe     17 972 64 68 1.1 92.4 17.4 
    Italy Alto Adige 0.8 2000-2002 465 938 504 64 68 0.0 99.0 5.0 
Biella 0.3 2000-2002 187 983 370 66 70 0.3 95.7 3.2 
Ferrara 0.6 2000-2002 347 156 611 67 71 0.8 98.7 7.9 
Firenze 2.0 2000-2002 1 162 973 1941 64 68 0.6 69.0 21.5 
Friuli Venezia Giulia 2.1 2000-2002 1 192 711 1918 65 69 1.6 99.6 29.1 
Genova 1.6 2000 900 735 579 67 70 0.9 79.3 7.8 
Modena 1.1 2000-2002 638 743 1045 63 68 0.3 99.4 2.6 
Napoli 0.9 2000 546 399 192 51 57 1.0 76.6 23.6 
Parma 0.7 2000-2002 402 788 769 66 70 0.0 100.0 15.9 
Ragusa 0.5 2000-2002 295 496 453 64 69 1.6 95.4 4.9 
Reggio Emilia‡ 0.8 2000-2002 462 469 734 65 69 0.1 97.3 50.7 
Romagna 1.7 2000-2002 991 045 1713 66 70 2.3 97.5 11.7 
Salerno 1.9 2000-2001 1 082 710 700 61 66 2.7 93.4 22.7 
Sassari 0.8 2000-2002 469 200 576 62 66 0.3 96.7 5.6 
Torino 1.6 2000-2001 900 408 887 64 67 1.0 95.4 22.0 
Trento 0.8 2000 477 859 200 66 70 0.5 96.5 9.0 
Umbria‡ 1.5 2000-2002 833 506 1125 64 69 0.7 77.6 38.8 
Veneto 3.5 2000 2 015 290 944 64 68 1.9 92.6 14.5 
    Malta Malta 100.0 2000-2002 388 752 378 60 65 0.0 98.4 17.5 
    Slovenia Slovenia 100.0 2000-2002 1 990 625 1652 60 66 0.9 100.0 8.8 
    Spain Girona 1.3 2000-2002 558 649 681 64 70 3.4 95.5 5.7 
Eastern Europe     6550 60 65 9.8 91.4 14.5 
    Czech Republic West Bohemia 8.3 2000-2002 854 583 839 61 65 7.0 91.9 12.8 
    Poland Cracow‡ 1.9 2000-2002 731 162 497 60 65 8.5 82.9 34.2 
Kielce 3.1 2000-2002 1 325 260 972 60 66 0.0 89.2 23.5 
Warsaw 4.2 2000-2002 1 673 830 1130 61 66 0.0 97.2 13.6 
    Slovakia Slovakia 100.0 2000-2002 5 385 464 3112 58 64 17.3 91.2 9.3 
Total     97 521 64 69 3.2 92.7 17.6 
*

Proportion of national population covered by each registry in 1995-1999.

Unknown morphology (NOS) includes the following ICD-O-3 codes: 9590, 9591, 9800, 9801, 9805, 9820, 9832, and 9860.

CR was excluded from the final analysis because NOS cases exceeded 30%.

To obtain a set of cases with adequately specified morphology, we excluded CRs for which not otherwise specified (NOS) morphology constituted ≥ 30% of cases. The ICD-O-3 NOS codes are: lymphoma, 9590; non-Hodgkin lymphoma (NHL), 9591; lymphatic leukemia, 9820; leukemia, 9832; acute leukemia, 9800 and 9801; ambiguous lineage, 9805; and myeloid leukemia, 9860. The CRs of Austria, Cracow (Poland), Reggio Emilia (Italy), and Umbria (Italy) were excluded for this reason. The resulting study population, from the remaining 44 CRs, consisted of 88 167 cases: 66 371 lymphoid and 21 796 myeloid.

Data completeness

The present dataset was collected principally for the purposes of survival analysis. To investigate incidence completeness, the age-standardized incidence rates for Hodgkin lymphoma (HL), immunoproliferative disease, multiple myeloma, and myeloid leukemia, in the present dataset were compared with the incidence rates published in volume IX of Cancer Incidence in 5 Continents (CI5),1  for the same CRs over the same incidence period. CI5 is the official publication of population-based CRs worldwide and can be considered the “gold standard” because only data from CRs satisfying CI5's stringent criteria for data quality and completeness are published. The results of the comparison (supplemental Table 1, available on the Blood Web site; see the Supplemental Materials link at the top of the online article) showed, in all cases, that age-standardized incidence rates were closely similar, indicating that our data were as complete as those of CI5.

HM categories

ICD-O-3 codes for HMs were grouped into the 2 main disease lineages (lymphoid and myeloid) according to WHO indications. In accord with the HAEMACARE7  and InterLymph9  recommendations, lymphoid malignancies were grouped into 5 major categories (Table 2): HL, mature B-cell neoplasms, mature T-cell and natural killer cell neoplasms (T-NK), lymphoblastic lymphoma/acute (precursor cell) lymphatic leukemia (LL/ALL), and lymphoid NOS. These groups were subdivided according to lineage, again in accord with WHO and HAEMACARE (Table 2). Specifically, small B-cell lymphocytic lymphoma (SBLL)/chronic lymphatic leukemia (CLL) were analyzed together, as were Burkitt lymphoma and Burkitt leukemia (as noted previously). LL/ALL were divided into B-cell, T-cell, and NOS types. Within the mature B-cell neoplasm category, mature B-cell leukemia includes prolymphocytic leukemia B-cell type and mature hairy cell B leukemia, and plasma cell neoplasms were a major subcategory.

Table 2

Number of cases and crude incidence rates (IR) per 100 000 for lymphoid malignancies by sex and morphologic type diagnosed in 2000-2002 and archived in 44 European CRs

HAEMACARE groupings ICD-O-3 code ICD-O-3 description No. of cases All
 
Males
 
Females
 
IR 95% CI IR 95% CI IR 95% CI 
HL   5571 2.49 (2.42-2.55) 2.81 (2.71-2.91) 2.18 (2.09-2.26) 

 
    HL, nodular lymphocyte predominance 9659 HL, nodular lymphocyte predominance 195 0.09 (0.08-0.10) 0.12 (0.10-0.15) 0.05 (0.04-0.07) 

 
    Classic HL   5376 2.40 (2.34-2.47) 2.69 (2.59-2.79) 2.12 (2.04-2.21) 

 
 9650 HL, NOS 996 0.44 (0.42-0.47) 0.52 (0.48-0.57) 0.37 (0.34-0.41) 
 9661 Hodgkin granuloma (obsolete)        
 9662 Hodgkin sarcoma (obsolete)        
 
 
 9651 HL, lymphocyte rich 217 0.10 (0.08-0.11) 0.13 (0.11-0.15) 0.07 (0.05-0.08) 
 
 
 9663 HL, nodular sclerosis, NOS 3165 1.41 (1.36-1.46) 1.45 (1.38-1.53) 1.37 (1.31-1.44) 
 9664 HL, nodular sclerosis cellular phase        
 9665 HL, nodular sclerosis grade 1        
 9667 HL, nodular sclerosis grade 2        
 
 
 9652 HL, mixed cellularity, NOS 909 0.41 (0.38-0.43) 0.53 (0.49-0.58) 0.28 (0.25-0.32) 
 
 
 9653 HL, lymphocyte depletion, NOS 89 0.04 (0.03-0.05) 0.05 (0.04-0.07) 0.03 (0.02-0.04) 
 9654 HL, lymphocyte depletion, diffuse fibrosis        
 9655 HL, lymphocyte depletion, reticular        

 
Mature B-cell neoplasms   42 855 19.14 (18.96-19.32) 21.30 (21.03-21.57) 17.07 (16.83-17.31) 

 
    SBLL/CLL 9670 Malignant lymphoma, small B-cell lymphocytic, NOS 11 019 4.92 (4.83-5.01) 5.87 (5.73-6.02) 4.01 (3.90-4.13) 
 9823 B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma        

 
    Immunoproliferative diseases 9671 Malignant lymphoma, lymphoplasmacytic 1859 0.83 (0.79-0.87) 1.00 (0.94-1.06) 0.67 (0.63-0.72) 
 9760 Immunoproliferative disease, NOS        
 9761 Waldenström macroglobulinemia        
 9762 Heavy chain disease, NOS        

 
    Mantle cell/centrocytic lymphoma 9673 Mantle cell lymphoma 1012 0.45 (0.42-0.48) 0.64 (0.60-0.69) 0.27 (0.24-0.30) 

 
    Follicular B-cell lymphoma 9690 Follicular lymphoma, NOS 4881 2.18 (2.12-2.24) 2.10 (2.01-2.19) 2.26 (2.17-2.35) 
 9691 Follicular lymphoma, grade 2        
 9695 Follicular lymphoma, grade 1        
 9698 Follicular lymphoma, grade 3        

 
    Diffuse B-cell lymphoma 9675 Malignant lymphoma, mixed small and large cell, diffuse (obsolete) 8538 3.81 (3.73-3.89) 4.06 (3.95-4.19) 3.57 (3.46-3.68) 
 9678 Primary effusion lymphoma        
 9679 Mediastinal large B-cell lymphoma        
 9680 Malignant lymphoma, large B-cell, diffuse, NOS        
 9684 Malignant lymphoma, large B-cell, diffuse, immunoblastic, NOS        

 
    Burkitt lymphoma/leukemia 9687 Burkitt lymphoma, NOS 488 0.22 (0.20-0.24) 0.31 (0.27-0.34) 0.13 (0.11-0.16) 
 9826 Burkitt cell leukemia        

 
    Marginal zone lymphoma 9689 Splenic marginal zone B-cell lymphoma 950 0.42 (0.40-0.45) 0.40 (0.36-0.44) 0.45 (0.41-0.49) 
 9699 Marginal zone B-cell lymphoma, NOS/mucosa-associated lymphoid tissue lymphoma        
 9764 Immunoproliferative small intestinal disease (Mediterranean lymphoma)        

 
    Mature B-cell leukemia 9833 Prolymphocytic leukemia, B-cell type 652 0.29 (0.27-0.31) 0.46 (0.42-0.50) 0.13 (0.11-0.15) 
 9940 Hairy cell leukemia        

 
    Plasma cell neoplasms   13 456 6.01 (5.91-6.11) 6.46 (6.31-6.61) 5.58 (5.44-5.72) 
 
 
 9732 Multiple myeloma 12 192 5.44 (5.35-5.54) 5.85 (5.70-5.99) 5.06 (4.93-5.19) 
 
 
 9733 Plasma cell leukemia 92 0.04 (0.03-0.05) 0.04 (0.03-0.05) 0.05 (0.03-0.06) 
 
 
 9731 Plasmacytoma, NOS 1172 0.52 (0.49-0.55) 0.58 (0.53-0.62) 0.47 (0.43-0.51) 
 9734 Plasmacytoma, extramedullary        

 
Mature T-cell and NK-cell neoplasms   2527 1.13 (1.08-1.17) 1.41 (1.34-1.48) 0.86 (0.81-0.92) 

 
    Cutaneous T-cell lymphoma 9700 Mycosis fungoides 1208 0.54 (0.51-0.57) 0.68 (0.64-0.73) 0.40 (0.37-0.44) 
 9701 Sézary syndrome        
 9708 Subcutaneous T panniculitis-like T-cell lymphoma        
 9709 Cutaneous T-cell lymphoma, NOS        
 9718 Primary cutaneous CD30+ T-cell lymphoproliferative disorder        
    Other T-cell lymphomas 9702 Mature T-cell lymphoma, NOS 1319 0.59 (0.56-0.62) 0.72 (0.67-0.78) 0.46 (0.42-0.50) 
 9705 Angioimmunoblastic T-cell lymphoma        
 9714 Anaplastic large cell lymphoma, T-cell and null cell type        
 9716 Hepatosplenic γδ cell lymphoma        
 9717 Intestinal T-cell lymphoma        
 9948 Aggressive NK-cell leukemia        
 9719 NK/T-cell lymphoma, nasal and nasal-type        
 9827 Adult T-cell leukemia/lymphoma (HTLV-1 positive)        
 9831 T-cell large granular lymphocytic leukemia        
 9834 Prolymphocytic leukemia, T-cell type        

 
Lymphoblastic lymphoma/acute (precursor cell) lymphatic leukemia 2863 1.28 (1.23-1.33) 1.44 (1.37-1.51) 1.12 (1.06-1.19) 

 
    B-cell 9728 Precursor B-cell lymphoblastic lymphoma 190 0.08 (0.07-0.10) 0.09 (0.07-0.11) 0.08 (0.06-0.10) 
 9836 Precursor B-cell lymphoblastic leukemia        

 
    T-cell 9729 Precursor T-cell lymphoblastic lymphoma 64 0.03 (0.02-0.04) 0.04 (0.03-0.06) 0.01 (0.01-0.02) 
 9837 Precursor T-cell lymphoblastic leukemia        

 
    NOS 9727 Precursor cell lymphoblastic lymphoma, NOS 2609 1.17 (1.12-1.21) 1.31 (1.24-1.38) 1.03 (0.97-1.09) 
 9835 Precursor cell lymphoblastic leukemia, NOS        

 
Unknown lymphoid neoplasms   12 547 5.60 (5.51-5.70) 5.87 (5.72-6.01) 5.35 (5.22-5.49) 

 
    Lymphoma, NOS 9590 Malignant lymphoma, NOS 4803 2.14 (2.08-2.21) 2.21 (2.12-2.30) 2.09 (2.00-2.17) 

 
    NHL, NOS 9591 Malignant lymphoma, NHL, NOS 7450 3.33 (3.25-3.40) 3.51 (3.40-3.62) 3.15 (3.05-3.25) 

 
    Lymphatic leukemia, NOS 9820 Lymphoid leukemia, NOS 294 0.13 (0.12-0.15) 0.15 (0.13-0.17) 0.12 (0.10-0.14) 
 9832 Prolymphocytic leukemia, NOS        

 
All lymphoid malignancies  66 371 29.64 (29.41-29.86) 32.83 (32.49-33.17) 26.59 (26.29-26.89) 
HAEMACARE groupings ICD-O-3 code ICD-O-3 description No. of cases All
 
Males
 
Females
 
IR 95% CI IR 95% CI IR 95% CI 
HL   5571 2.49 (2.42-2.55) 2.81 (2.71-2.91) 2.18 (2.09-2.26) 

 
    HL, nodular lymphocyte predominance 9659 HL, nodular lymphocyte predominance 195 0.09 (0.08-0.10) 0.12 (0.10-0.15) 0.05 (0.04-0.07) 

 
    Classic HL   5376 2.40 (2.34-2.47) 2.69 (2.59-2.79) 2.12 (2.04-2.21) 

 
 9650 HL, NOS 996 0.44 (0.42-0.47) 0.52 (0.48-0.57) 0.37 (0.34-0.41) 
 9661 Hodgkin granuloma (obsolete)        
 9662 Hodgkin sarcoma (obsolete)        
 
 
 9651 HL, lymphocyte rich 217 0.10 (0.08-0.11) 0.13 (0.11-0.15) 0.07 (0.05-0.08) 
 
 
 9663 HL, nodular sclerosis, NOS 3165 1.41 (1.36-1.46) 1.45 (1.38-1.53) 1.37 (1.31-1.44) 
 9664 HL, nodular sclerosis cellular phase        
 9665 HL, nodular sclerosis grade 1        
 9667 HL, nodular sclerosis grade 2        
 
 
 9652 HL, mixed cellularity, NOS 909 0.41 (0.38-0.43) 0.53 (0.49-0.58) 0.28 (0.25-0.32) 
 
 
 9653 HL, lymphocyte depletion, NOS 89 0.04 (0.03-0.05) 0.05 (0.04-0.07) 0.03 (0.02-0.04) 
 9654 HL, lymphocyte depletion, diffuse fibrosis        
 9655 HL, lymphocyte depletion, reticular        

 
Mature B-cell neoplasms   42 855 19.14 (18.96-19.32) 21.30 (21.03-21.57) 17.07 (16.83-17.31) 

 
    SBLL/CLL 9670 Malignant lymphoma, small B-cell lymphocytic, NOS 11 019 4.92 (4.83-5.01) 5.87 (5.73-6.02) 4.01 (3.90-4.13) 
 9823 B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma        

 
    Immunoproliferative diseases 9671 Malignant lymphoma, lymphoplasmacytic 1859 0.83 (0.79-0.87) 1.00 (0.94-1.06) 0.67 (0.63-0.72) 
 9760 Immunoproliferative disease, NOS        
 9761 Waldenström macroglobulinemia        
 9762 Heavy chain disease, NOS        

 
    Mantle cell/centrocytic lymphoma 9673 Mantle cell lymphoma 1012 0.45 (0.42-0.48) 0.64 (0.60-0.69) 0.27 (0.24-0.30) 

 
    Follicular B-cell lymphoma 9690 Follicular lymphoma, NOS 4881 2.18 (2.12-2.24) 2.10 (2.01-2.19) 2.26 (2.17-2.35) 
 9691 Follicular lymphoma, grade 2        
 9695 Follicular lymphoma, grade 1        
 9698 Follicular lymphoma, grade 3        

 
    Diffuse B-cell lymphoma 9675 Malignant lymphoma, mixed small and large cell, diffuse (obsolete) 8538 3.81 (3.73-3.89) 4.06 (3.95-4.19) 3.57 (3.46-3.68) 
 9678 Primary effusion lymphoma        
 9679 Mediastinal large B-cell lymphoma        
 9680 Malignant lymphoma, large B-cell, diffuse, NOS        
 9684 Malignant lymphoma, large B-cell, diffuse, immunoblastic, NOS        

 
    Burkitt lymphoma/leukemia 9687 Burkitt lymphoma, NOS 488 0.22 (0.20-0.24) 0.31 (0.27-0.34) 0.13 (0.11-0.16) 
 9826 Burkitt cell leukemia        

 
    Marginal zone lymphoma 9689 Splenic marginal zone B-cell lymphoma 950 0.42 (0.40-0.45) 0.40 (0.36-0.44) 0.45 (0.41-0.49) 
 9699 Marginal zone B-cell lymphoma, NOS/mucosa-associated lymphoid tissue lymphoma        
 9764 Immunoproliferative small intestinal disease (Mediterranean lymphoma)        

 
    Mature B-cell leukemia 9833 Prolymphocytic leukemia, B-cell type 652 0.29 (0.27-0.31) 0.46 (0.42-0.50) 0.13 (0.11-0.15) 
 9940 Hairy cell leukemia        

 
    Plasma cell neoplasms   13 456 6.01 (5.91-6.11) 6.46 (6.31-6.61) 5.58 (5.44-5.72) 
 
 
 9732 Multiple myeloma 12 192 5.44 (5.35-5.54) 5.85 (5.70-5.99) 5.06 (4.93-5.19) 
 
 
 9733 Plasma cell leukemia 92 0.04 (0.03-0.05) 0.04 (0.03-0.05) 0.05 (0.03-0.06) 
 
 
 9731 Plasmacytoma, NOS 1172 0.52 (0.49-0.55) 0.58 (0.53-0.62) 0.47 (0.43-0.51) 
 9734 Plasmacytoma, extramedullary        

 
Mature T-cell and NK-cell neoplasms   2527 1.13 (1.08-1.17) 1.41 (1.34-1.48) 0.86 (0.81-0.92) 

 
    Cutaneous T-cell lymphoma 9700 Mycosis fungoides 1208 0.54 (0.51-0.57) 0.68 (0.64-0.73) 0.40 (0.37-0.44) 
 9701 Sézary syndrome        
 9708 Subcutaneous T panniculitis-like T-cell lymphoma        
 9709 Cutaneous T-cell lymphoma, NOS        
 9718 Primary cutaneous CD30+ T-cell lymphoproliferative disorder        
    Other T-cell lymphomas 9702 Mature T-cell lymphoma, NOS 1319 0.59 (0.56-0.62) 0.72 (0.67-0.78) 0.46 (0.42-0.50) 
 9705 Angioimmunoblastic T-cell lymphoma        
 9714 Anaplastic large cell lymphoma, T-cell and null cell type        
 9716 Hepatosplenic γδ cell lymphoma        
 9717 Intestinal T-cell lymphoma        
 9948 Aggressive NK-cell leukemia        
 9719 NK/T-cell lymphoma, nasal and nasal-type        
 9827 Adult T-cell leukemia/lymphoma (HTLV-1 positive)        
 9831 T-cell large granular lymphocytic leukemia        
 9834 Prolymphocytic leukemia, T-cell type        

 
Lymphoblastic lymphoma/acute (precursor cell) lymphatic leukemia 2863 1.28 (1.23-1.33) 1.44 (1.37-1.51) 1.12 (1.06-1.19) 

 
    B-cell 9728 Precursor B-cell lymphoblastic lymphoma 190 0.08 (0.07-0.10) 0.09 (0.07-0.11) 0.08 (0.06-0.10) 
 9836 Precursor B-cell lymphoblastic leukemia        

 
    T-cell 9729 Precursor T-cell lymphoblastic lymphoma 64 0.03 (0.02-0.04) 0.04 (0.03-0.06) 0.01 (0.01-0.02) 
 9837 Precursor T-cell lymphoblastic leukemia        

 
    NOS 9727 Precursor cell lymphoblastic lymphoma, NOS 2609 1.17 (1.12-1.21) 1.31 (1.24-1.38) 1.03 (0.97-1.09) 
 9835 Precursor cell lymphoblastic leukemia, NOS        

 
Unknown lymphoid neoplasms   12 547 5.60 (5.51-5.70) 5.87 (5.72-6.01) 5.35 (5.22-5.49) 

 
    Lymphoma, NOS 9590 Malignant lymphoma, NOS 4803 2.14 (2.08-2.21) 2.21 (2.12-2.30) 2.09 (2.00-2.17) 

 
    NHL, NOS 9591 Malignant lymphoma, NHL, NOS 7450 3.33 (3.25-3.40) 3.51 (3.40-3.62) 3.15 (3.05-3.25) 

 
    Lymphatic leukemia, NOS 9820 Lymphoid leukemia, NOS 294 0.13 (0.12-0.15) 0.15 (0.13-0.17) 0.12 (0.10-0.14) 
 9832 Prolymphocytic leukemia, NOS        

 
All lymphoid malignancies  66 371 29.64 (29.41-29.86) 32.83 (32.49-33.17) 26.59 (26.29-26.89) 
*

Eight cases of composite HL and NHL (ICD-O-3 code 9596) not shown in Table 2 have been included in the totals.

T-NK-cell neoplasms were divided into cutaneous and other T-cell neoplasms. Unknown lymphoid neoplasms were separated into lymphoma NOS, NHL NOS, and lymphatic leukemia NOS.

Myeloid malignancies (Table 3) were grouped into 5 large categories: acute myeloid leukemia (AML), myeloproliferative neoplasms, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasms, and unknown myeloid neoplasms. AML was subdivided into 5 subgroups, in accord with WHO indications. Myeloproliferative neoplasms were subdivided into chronic myeloid leukemia (CML) and other morphologic subgroups (other myeloproliferative neoplasms). Unknown myeloid neoplasms were divided into leukemia NOS and myeloid leukemia NOS.

Table 3

Number of cases and crude incidence rate (IR) per 100 000 for myeloid malignancies diagnosed in 2000-2002 archived in 44 European CRs by sex and morphologic type

HAEMACARE groupings ICD-O-3 code ICD-O-3 description No. of cases Total
 
Males
 
Females
 
IR 95% CI IR 95% CI IR 95% CI 
Acute myeloid leukemia  8107 3.62 (3.54-3.70) 3.90 (3.78-4.02) 3.35 (3.25-3.46) 

 
    Subgroup 1 9840 Acute erythroid leukemia 7545 3.37 (3.29-3.45) 3.64 (3.53-3.76) 3.11 (3.01-3.21) 
 9861 AML, NOS        
 9867 Acute myelomonocytic leukemia        
 9870 Acute basophilic leukemia        
 9872 AML, minimal differentiation        
 9873 AML without maturation        
 9874 AML with maturation        
 9891 Acute monocytic leukemia        
 9910 Acute megakaryoblastic leukemia        
 9930 Myeloid sarcoma        

 
    Subgroup 2 9866 Acute promyelocytic leukemia t(15; 17) (q22; q11-12) 311 0.14 (0.12-0.16) 0.13 (0.11-0.15) 0.15 (0.13-0.17) 
 9871 AML with abnormal marrow eosinophils        
 9896 AML, t(8,21) (q22,q22)        
 9897 AML, 11q23 abnormalities        

 
    Subgroup 3 9895 AML, with multilineage dysplasia 137 0.06 (0.05-0.07) 0.07 (0.06-0.09) 0.05 (0.04-0.07) 
 9984 Refractory anemia with excess blasts in transformation (obsolete)        

 
    Subgroup 4 9931 Acute panmyelosis with myelofibrosis 106 0.05 (0.04-0.06) 0.05 (0.04-0.07) 0.04 (0.03-0.05) 

 
Myeloproliferative neoplasms   7474 3.34 (3.26-3.41) 3.50 (3.39-3.62) 3.18 (3.08-3.28) 

 
    CML 9863 CML, NOS 2468 1.10 (1.06-1.15) 1.23 (1.17-1.30) 0.98 (0.92-1.04) 
 9875 Chronic myelogenous leukemia, BCR/ABL positive        

 
    Other myeloproliferative neoplasms†   5006 2.24 (2.17-2.30) 2.27 (2.19-2.36) 2.20 (2.11-2.29) 

 
        Subgroup 1 9950 Polycythemia vera 3431 1.53 (1.48-1.58) 1.57 (1.49-1.64) 1.50 (1.43-1.57) 
 9961 Myelosclerosis with myeloid metaplasia        
 9962 Essential thrombocythemia        
 9963 Chronic neutrophilic leukemia        
 9964 Hypereosinophilic syndrome        

 
        Subgroup 2 9960 Chronic myeloproliferative disease, NOS 1546 0.69 (0.66-0.73) 0.69 (0.64-0.74) 0.69 (0.64-0.74) 

 
Myelodysplastic syndrome   4074 1.82 (1.76-1.88) 2.03 (1.95-2.12) 1.62 (1.54-1.69) 

 
 9980 Refractory anemia        
 9982 Refractory anemia with sideroblasts        
 9983 Refractory anemia with excess blasts        
 9985 Refractory cytopenia with multilineage dysplasia        
 9986 Myelodysplastic syndrome 5q deletion        
 9989 Myelodysplastic syndrome, NOS        

 
Myelodysplastic/myeloproliferative neoplasms   776 0.35 (0.32-0.37) 0.42 (0.38-0.46) 0.28 (0.25-0.31) 

 
 9945 Chronic myelomonocytic leukemia        
 9876 Atypical CML, BCR/ABL-1 negative        
 9946 Juvenile myelomonocytic leukemia        
 9975 Myelodysplastic/myeloproliferative neoplasm, unclassifiable        

 
Unknown myeloid neoplasms   1365 0.61 (0.58-0.64) 0.66 (0.61-0.71) 0.56 (0.52-0.61) 

 
    Leukemia, NOS 9800 Leukemia, NOS 1010 0.45 (0.42-0.48) 0.48 (0.44-0.53) 0.42 (0.38-0.46) 
 9801 Acute leukemia, NOS        
 9805 Acute leukemia, ambiguous lineage        

 
    Myeloid leukemia, NOS 9860 Myeloid leukemia, NOS 355 0.16 (0.14-0.18) 0.17 (0.15-0.20) 0.14 (0.12-0.17) 

 
All myeloid malignancies   21 796 9.73 (9.60-9.86) 10.51 (10.32-10.70) 8.99 (8.82-9.17) 
HAEMACARE groupings ICD-O-3 code ICD-O-3 description No. of cases Total
 
Males
 
Females
 
IR 95% CI IR 95% CI IR 95% CI 
Acute myeloid leukemia  8107 3.62 (3.54-3.70) 3.90 (3.78-4.02) 3.35 (3.25-3.46) 

 
    Subgroup 1 9840 Acute erythroid leukemia 7545 3.37 (3.29-3.45) 3.64 (3.53-3.76) 3.11 (3.01-3.21) 
 9861 AML, NOS        
 9867 Acute myelomonocytic leukemia        
 9870 Acute basophilic leukemia        
 9872 AML, minimal differentiation        
 9873 AML without maturation        
 9874 AML with maturation        
 9891 Acute monocytic leukemia        
 9910 Acute megakaryoblastic leukemia        
 9930 Myeloid sarcoma        

 
    Subgroup 2 9866 Acute promyelocytic leukemia t(15; 17) (q22; q11-12) 311 0.14 (0.12-0.16) 0.13 (0.11-0.15) 0.15 (0.13-0.17) 
 9871 AML with abnormal marrow eosinophils        
 9896 AML, t(8,21) (q22,q22)        
 9897 AML, 11q23 abnormalities        

 
    Subgroup 3 9895 AML, with multilineage dysplasia 137 0.06 (0.05-0.07) 0.07 (0.06-0.09) 0.05 (0.04-0.07) 
 9984 Refractory anemia with excess blasts in transformation (obsolete)        

 
    Subgroup 4 9931 Acute panmyelosis with myelofibrosis 106 0.05 (0.04-0.06) 0.05 (0.04-0.07) 0.04 (0.03-0.05) 

 
Myeloproliferative neoplasms   7474 3.34 (3.26-3.41) 3.50 (3.39-3.62) 3.18 (3.08-3.28) 

 
    CML 9863 CML, NOS 2468 1.10 (1.06-1.15) 1.23 (1.17-1.30) 0.98 (0.92-1.04) 
 9875 Chronic myelogenous leukemia, BCR/ABL positive        

 
    Other myeloproliferative neoplasms†   5006 2.24 (2.17-2.30) 2.27 (2.19-2.36) 2.20 (2.11-2.29) 

 
        Subgroup 1 9950 Polycythemia vera 3431 1.53 (1.48-1.58) 1.57 (1.49-1.64) 1.50 (1.43-1.57) 
 9961 Myelosclerosis with myeloid metaplasia        
 9962 Essential thrombocythemia        
 9963 Chronic neutrophilic leukemia        
 9964 Hypereosinophilic syndrome        

 
        Subgroup 2 9960 Chronic myeloproliferative disease, NOS 1546 0.69 (0.66-0.73) 0.69 (0.64-0.74) 0.69 (0.64-0.74) 

 
Myelodysplastic syndrome   4074 1.82 (1.76-1.88) 2.03 (1.95-2.12) 1.62 (1.54-1.69) 

 
 9980 Refractory anemia        
 9982 Refractory anemia with sideroblasts        
 9983 Refractory anemia with excess blasts        
 9985 Refractory cytopenia with multilineage dysplasia        
 9986 Myelodysplastic syndrome 5q deletion        
 9989 Myelodysplastic syndrome, NOS        

 
Myelodysplastic/myeloproliferative neoplasms   776 0.35 (0.32-0.37) 0.42 (0.38-0.46) 0.28 (0.25-0.31) 

 
 9945 Chronic myelomonocytic leukemia        
 9876 Atypical CML, BCR/ABL-1 negative        
 9946 Juvenile myelomonocytic leukemia        
 9975 Myelodysplastic/myeloproliferative neoplasm, unclassifiable        

 
Unknown myeloid neoplasms   1365 0.61 (0.58-0.64) 0.66 (0.61-0.71) 0.56 (0.52-0.61) 

 
    Leukemia, NOS 9800 Leukemia, NOS 1010 0.45 (0.42-0.48) 0.48 (0.44-0.53) 0.42 (0.38-0.46) 
 9801 Acute leukemia, NOS        
 9805 Acute leukemia, ambiguous lineage        

 
    Myeloid leukemia, NOS 9860 Myeloid leukemia, NOS 355 0.16 (0.14-0.18) 0.17 (0.15-0.20) 0.14 (0.12-0.17) 

 
All myeloid malignancies   21 796 9.73 (9.60-9.86) 10.51 (10.32-10.70) 8.99 (8.82-9.17) 
*

Eight cases of therapy-related AML, NOS, and therapy-related myelodysplastic syndrome, NOS (ICD-O-3 codes 9920 and 9987, respectively) not shown in Table 3 were included with acute myeloid leukemia.

Twenty-nine cases of mastocytoma NOS/mast cell sarcoma, malignant mastocytosis, and mast cell leukemia (ICD-O-3 codes 9740, 9741, and 9742, respectively) not shown in Table 3 were included with other myeloproliferative neoplasms.

Statistical analysis

We estimated crude incidence rates per 100 000 with 95% confidence intervals (95% confidence interval [CI]) for each sex and each morphologic subcategory (as shown in the left column of Tables 2, 3) by CR, using CR area-specific populations.10  We also estimated incidence according to age at diagnosis, grouped into 6 categories: 0-14, 15-44, 45-54, 55-64, 65-74, and 75-99 years. Finally, we estimated, using the direct method, age-standardized incidence rates per 100 000 for each CR area, and for the entire dataset, for each of the HAEMACARE disease categories (5 lymphoid and 5 myeloid) defined in “HM categories,” considering the European population as standard. The calculations and analyses were carried out using the SEER STAT software package, Version 6.4.4. (Information Management Services Inc, and Surveillance Research Program of the Division of Cancer Control and Population Sciences, National Cancer Institute).

Results

Table 1 shows some indicators of data quality as well as mean and median ages at diagnosis. Overall, 92.7% (range, 64.3%-100.0%) of cases were microscopically verified, with less than 80.0% microscopically verified in 6 CRs representing 9% of the average population covered. Overall, 3.2% (range, 0.0%-17.3%) of cases were known by death certificate only, or discovered at autopsy, with more than 5% in 6 CRs, representing 27% of the average population covered. Overall, 17.6% (range, 0.8%-50.7%) of cases were NOS: 15.9% of lymphoid cases (lymphoma NOS, NHL NOS, and lymphatic leukemia NOS) and 1.6% of myeloid cases (leukemia NOS; acute leukemia NOS; acute leukemia, ambiguous lineage; and myeloid leukemia NOS). Mean overall age was 64 years, range of means 60 years (Eastern Europe) to 65 years (Northern Europe and United Kingdom and Ireland); median age was 69 years, range of medians 65 (Eastern Europe) to 70 years (Northern Europe). A total of 66 371 lymphoid malignancies incident in 2000-2002 in the 44 CRs were included in the analyses (Table 2). The overall crude incidence rate of lymphoid malignancies was 29.64 per 100 000: 32.83 for males and 26.59 for females.

Considering specific lymphoid malignancy subgroups, the overall crude incidence rate of HL was 2.49, the commonest subtype being classic HL with nodular sclerosis. The overall crude incidence rate of mature B-cell neoplasms was 19.14. The most common subtypes were SBLL/CLL (4.92), diffuse B-cell lymphoma (3.81), and follicular B-cell lymphoma (2.18). Immunoproliferative diseases, mantle cell/centrocytic lymphoma, Burkitt lymphoma/leukemia, marginal zone lymphoma, and mature B-cell leukemias (prolymphocytic and hairy cell) all had crude incidence rates of less than 1, whereas the incidence of plasma cell neoplasms, mainly multiple myeloma, was fairly high at 6.01.

The overall incidence of T-NK-cell neoplasms was 1.13, approximately one-half of which were cutaneous T-cell lymphomas and the other half T-cell lymphomas. The crude incidence of LL/ALL was 1.28, for most of which (1.17) the B versus T type was unknown (ie, NOS). The crude incidence of unknown types of lymphoid neoplasm was 5.60, including NHL NOS at 3.33, based on 7450 cases; and lymphoma NOS at 2.14, based on 4803 cases. For most lymphoid malignancies, crude incidence was higher in men than in women.

Table 3 shows crude incidence rates for myeloid malignancies. A total of 21 796 myeloid malignancies, diagnosed in 2000-2002, were archived in the 44 European CRs. The overall crude incidence rate was 9.73: 10.51 in men and 8.99 in women.

Considering specific myeloid subgroups, the overall incidence rate of AML was 3.62. The most common AML was subgroup 1 (Table 3), with incidence 3.37, which includes AML NOS, and malignancies arising from various other myeloid lineages, such as myelomonocytic, monocytic, basophilic, erythroid, and megakaryoblastic forms. The incidence of subgroup 2, composed of promyelocytic leukemia and other AMLs with recurrent genetic abnormalities, was 0.14. There were 137 cases in subgroup 3, including AML with multilineage dysplasia and refractory anemia with excess blasts in transformation; 106 cases in subgroup 4, including acute panmyelosis with myelofibrosis and only 8 cases of therapy-related AML, NOS, or therapy-related myelodysplastic syndrome, NOS (not shown in Table 3).

There were 7474 incident cases of myeloproliferative neoplasms, with overall incidence 3.34. This category included CML (crude incidence 1.10) and other myeloproliferative neoplasms (2.24). The crude incidence of myelodysplastic syndrome was 1.82, whereas for myelodysplastic/myeloproliferative neoplasms mainly represented by chronic myelomonocytic leukemia (756 of 776 cases), incidence was 0.35.

The incidence of leukemia NOS was 0.45, based on 1010 cases and incidence of myeloid leukemia NOS was 0.16, based on 355 cases.

Like lymphoid malignancies, for most myeloid malignancies incidence was higher in males than females.

Figure 1 shows age-specific incidence rates (per 100 000) for lymphoid and myeloid malignancies, respectively, by broad HAEMACARE groupings and by age class. Incidence generally increased with age, reaching a maximum at 75-99 years. Notable exceptions were HL and LL/ALL: For HL, incidence was bimodal, peaking at 15-44 years (3.35; 95% CI, 3.23-3.47) and 65-74 years (2.80; 95% CI, 2.56-3.05). For LL/ALL, incidence was high at 0-14 years (3.59; 95% CI, 3.40-4.78), decreased to 0.53 (95% CI, 0.45-0.61) at 45-54 years and increased with advancing age thereafter (to 1.45; 95% CI, 1.27-1.65, at 75-99 years). The incidence trend with age for Burkitt lymphoma/leukemia also showed a trough, with a peak in childhood (0.26, 95% CI, 0.22-0.32), which declined at 15-44 years and 45-54 years (0.17; 95% CI, 0.14-0.19 and 0.17; 95% CI, 0.13-0.23) and increased subsequently, to 0.33 (95% CI, 0.25-0.43) at 75-99 years.

Figure 1

Age-specific incidence rates (per 100 000) for HMs diagnosed in 2000-2002 and archived by 44 European CRs by age class and morphologic type (HAEMACARE groupings). (A) Lymphoid malignancies. (B) Myeloid malignancies.

Figure 1

Age-specific incidence rates (per 100 000) for HMs diagnosed in 2000-2002 and archived by 44 European CRs by age class and morphologic type (HAEMACARE groupings). (A) Lymphoid malignancies. (B) Myeloid malignancies.

Figure 2 shows age-standardized incidence rates by European region for broad HAEMACARE groupings. Considering first lymphoid malignancies, with reference to the European average, HL incidence was significantly higher in Southern Europe (2.97) and significantly lower in Eastern Europe (2.12) and Northern Europe (2.04). For SBLL/CLL, incidence rates were closely similar across the 5 regions. For diffuse B-cell lymphoma, incidence was significantly lower in Eastern Europe (1.79) and Northern Europe (0.79), with no remarkable differences between other European regions. For follicular B-cell lymphoma, incidence was significantly lower in Eastern Europe (0.83) and significantly higher in Central Europe (2.47) and United Kingdom and Ireland (2.19). For immunoproliferative diseases, incidence was significantly lower than the European average in the United Kingdom and Ireland (0.48) and Eastern Europe (0.47). For T-NK-cell neoplasms, incidence was significantly higher in Southern Europe (1.46) and lower in Eastern Europe (0.46) and Northern Europe (0.77). For LL/ALL, incidence was also significantly higher in Southern Europe (1.78). For plasma cell neoplasms, incidence was significantly lower in Eastern Europe (3.52) and higher in United Kingdom and Ireland (4.89). For lymphoid malignancies of unknown type, incidence was significantly higher in Northern Europe (7.53), whereas for all lymphoid malignancies together, incidence was significantly lower in Eastern Europe (16.62) and higher in Southern Europe (26.84) and United Kingdom and Ireland (25.87).

Figure 2

Age-standardized incidence rates (per 100 000) for HMs diagnosed in 2000-2002 and archived by 44 European CRs by European region and morphologic type (HAEMACARE groupings). (A) Lymphoid malignancies. (B) Myeloid malignancies.

Figure 2

Age-standardized incidence rates (per 100 000) for HMs diagnosed in 2000-2002 and archived by 44 European CRs by European region and morphologic type (HAEMACARE groupings). (A) Lymphoid malignancies. (B) Myeloid malignancies.

Considering now myeloid malignancies, the incidence of AML was significantly lower than the European average in Eastern Europe (2.07) and higher in the United Kingdom and Ireland (3.24). The incidence of CML was significantly higher in Southern Europe (1.16), with no remarkable differences across the other areas. For myelodysplastic syndrome and other myeloproliferative neoplasms, incidence was significantly higher than the European average in United Kingdom and Ireland (2.08 and 2.35, respectively) and lower in Eastern Europe (0.27 and 0.35, respectively). For unknown myeloid neoplasms, incidence was highest in Southern Europe (0.73). For all myeloid malignancies (total), United Kingdom and Ireland had the highest incidence (9.22) and Eastern Europe the lowest (4.11).

Discussion

Incidence is one of the major measures of disease burden in a population (together with prevalence, mortality, and survival) and serves as an important guide the allocation of public health resources. Most previous studies on HM incidence divided the daunting number of HM subtypes into broad categories taking no account of the great variation in prognosis between diseases of similar cell lineage or maturation stage. For epidemiologic and public health purposes, it makes more sense to group diseases (defined by ICD-O-3 code) into categories useful for investigating prognosis and testing etiologic hypotheses because diseases arising from the same cell lineage may have similar etiologies, and are more compatible with clinical classifications than the broad categories used by CRs.

We considered only cases incident in 2000-2002, when the ICD-O-3 classification was being used by all CRs participating in this study. Nevertheless, the availability and quality of morphology data varied between CRs and countries. We therefore further restricted our analysis to CRs that had less than 30% of NOS cases, an arbitrary percentage nonetheless indicating a reasonably satisfactory level of detail of information on morphology. Even with this restriction, however, the numbers of cases with poorly defined morphology (particularly lymphoma NOS and NHL NOS) were relatively high. Centralized revision of slides would have improved the quality of our data, but the resources were not available for such a task.

On the positive side, the high concordance of incidence data with that published in CI51  supports the completeness of our incidence estimates for the HM categories compared.

In agreement with other studies,9,11,12  we found that incidence varied with HM type. Thus, lymphoid malignancies were more common than myeloid malignancies. In addition, for both these disease groupings, incidence increased steadily with advancing age. As for solid cancers, accumulating DNA damage and diminished immune surveillance with age have been suggested as causes of increasing cancer incidence with age.13 

In contrast to the general age trend, LL/ALL incidence peaked in children 0-14 years of age, HL incidence peaked in the 15- to 44-year age range, and there was a trough of the incidence of Burkitt lymphoma/leukemia at 15-44 years. The childhood peak in LL/ALL is well known1,2  and has been related to host susceptibility factors and response to antigens in early or prenatal life,14  to exposure to electromagnetic fields,15  or to exposure to benzene and other hydrocarbons from traffic during intrauterine life and childhood.16  The hypothesis that children are more susceptible than adults to the carcinogenic effects of benzene deserves further investigation.16  Paternal smoking has been significantly linked to childhood LL/ALL, Burkitt lymphoma/leukemia, and AML.17 

The bimodal age trend for HL incidence has been noted previously.1,2  It has been suggested that the HL incidence peak in children, which tends to affect children of poorer families, is due to an infectious agent. The peak in young adults, on the other hand, could result from infection by an agent that commonly attacks children in whom it rarely causes HL but is more likely to do so if it affects adolescents or young adults.18  The main candidate proposed as cause of HL (and other HMs) is Epstein-Barr virus.19 

We found that HM incidence was generally lower in women than men; this is a well-known phenomenon1,2  and could be in part the result of lower exposure to environmental and occupational risk factors in women than men. Thus, increased risk of lymphoid malignancies has been documented in farmers exposed to pesticides,20,21  in workers in industries using formaldehyde,22  and in those exposed to dioxins.23  Most workers in these sectors are male. In the years before the study period, the greater prevalence of HIV infection in men than women was probably responsible for the higher incidence of NHL in men24,25 ; however, the introduction of aggressive antiretroviral therapies in the mid 1990s appears to have lowered the incidence of NHL in HIV-infected persons.25,26  The higher prevalence of smoking27  and greater alcohol intake in men than women may also contribute to the higher incidence of all HMs in men than in women. However, results of studies on smoking status and NHL risk are conflicting,25  as are results of studies investigating the association between alcohol consumption and myeloid leukemia.28  Some studies indicate that alcohol consumption is associated with reduced risk of NHL.25  The incidence of most cancers (not only HMs) is lower in women than men.29  Cook et al suggested that “universal mechanisms” might increase male susceptibility to cancer.29  They also cited various possible explanatory hypotheses, including those noted earlier in this paragraph and hormonal and genetic differences between men and women. We found that the incidence of most HMs varied considerably across Europe, with lowest rates of both lymphoid and myeloid malignancies in Eastern Europe (Figure 2). As regards lymphoid malignancies, the highest incidence of HL, LL/ALL, and mature T-NK neoplasms was in Southern Europe, and of diffuse and follicular B-cell neoplasms in Central Europe. Conversely, the United Kingdom and Ireland had the highest incidence of AML, myelodysplastic syndrome, and other myeloproliferative neoplasms. High incidence of most lymphoid malignancies in Southern Europe has been reported by other studies.1,2  However, we are not aware of studies that have attempted to correlate known risk factors for HMs with regional variations in incidence (as opposed to incidence hotspots). It is noteworthy that the regional variation in incidence of all lymphoid malignancies was less marked than the variation for specific lymphoid subgroups. This suggests that the geographic variation for lymphoid subgroups may be the result of more coding and diagnostic practices, including variation among pathologists in applying the classification criteria, than regional differences in prevalence of risk factors (and hence real differences in incidence). In Northern Europe, the high incidence of NOS in contrast with the low incidence of diffuse B-cell lymphoma suggests that a substantial fraction of the latter was registered as unknown lymphoid neoplasms.

It is also noteworthy that there was considerably less geographic variation in the incidence of AML and CML than for myelodysplastic syndrome and for other myeloproliferative neoplasms (Figure 2B). For the first 2 entities, diagnostic and classification criteria have been stable for some time, whereas for the latter 2, important changes in classification have occurred.

The high incidence of NOS cases in the elderly suggests lower diagnostic intensity, in turn suggesting inadequate diagnostic workup/care, difficulties in accessing hospitals, or poverty in elderly patients. Elderly patients may also be considered by physicians to have poor prognoses (perhaps because of the frequent presence of comorbidities), and thus receive a suboptimal diagnostic workup.

Our finding of conspicuously low incidence rates for both lymphoid and myeloid malignancies in Eastern Europe is in line with Globocan data.2  This could reflect genuinely low HM incidence in this part of Europe but could also in part be the result of underreporting. When we analyzed age-specific incidence rates (data not shown), we found that for those aged up to 54 years the incidence of all lymphoid malignancies (and also of their main subtypes follicular and diffuse B-cell lymphomas) in Eastern Europe was similar to that in the other parts of Europe, whereas low incidence was conspicuous in the 75- to 99-year age group. Lower incidence in Eastern European elderly patients was particularly marked for LL/ALL, multiple myeloma, myeloproliferative neoplasms, and myelodysplastic syndrome. LL/ALL patients may escape registration because of death; the other 3 conditions can be diagnosed and treated on an outpatient basis and for this reason also probably escape cancer registration. It is possible, therefore, that these diseases are underdiagnosed in the elderly because of less thorough diagnostic investigation.30 

Epidemiologic studies using similar HM groupings and including the same ICD-O-3 codes as those used in the present study have been carried out in the United States.9,11,12  The age-standardized incidence rate (per 100 000) for all lymphoid malignancies recorded by 17 SEER CRs in 2001 to 2003 was considerably higher than the age-standardized incidence recorded in our study (33.42 vs 24.50), with greatest differences for diffuse B-cell lymphoma (6.80 vs 3.13) and SBLL/CLL (5.10 vs 3.79), with less marked differences for less common subtypes, which nevertheless were consistently lower in Europe.9 

Conversely, the age-standardized incidence rate for all myeloid malignancies in 1992-2001 reported by SEER (12 CRs) was somewhat closer to the age-standardized incidence recorded in our study (6.63 vs 7.55) with lower European figures for AML (3.93 vs 2.96) and CML (1.72 vs 0.92). In 2001-2003, the incidence of myelodysplastic syndrome was considerably higher in SEER than we found in Europe (3.48 vs 1.24).12 

The lower incidence of myelodysplastic syndrome in Europe is probably in part the result of European underreporting. The disease mainly affects elderly patients who are less probable to undergo a thorough diagnostic assessment than younger patients.30  Another possible explanation is “excessive” diagnostic activity in the United States, which could inflate incidence, especially in elderly patients in whom these diseases are relatively common.

In addition, myelodysplastic syndrome and the category “other myeloproliferative neoplasms” used to be considered nonmalignant and were not recorded by most European CRs until the adoption of ICD-O-3. Perhaps not all CRs systematically registered these diseases in 2000-2002. Analysis of 13 European CRs with stable incidence rates for myelodysplastic syndrome and other myeloproliferative neoplasms over the study period supports the hypothesis of underreporting in the other CRs. In these 13 CRs, the age-standardized incidence rate was higher than in all 44 CRs for myelodysplastic syndrome (1.97; 95% CI, 1.90-2.04 vs 1.24; 95% CI, 1.20-1.28) and other myeloproliferative neoplasms (2.70; 95% CI, 2.62-2.79 vs 1.76; 95% CI, 1.71-1.81) and closer to the SEER figures. This finding reinforces the idea that the geographic differences in incidence of these diseases in Europe are in part attributable to differences in diagnostic and registration criteria.

In conclusion, our data show that HM incidence by morphologic groupings varies across Europe. Differences in diagnostic and registration criteria across Europe contribute to these differences complicating interpretation, and emphasizing that the quality of HM data needs to be improved. If the quality of data registration improved and the HM classification system remained relatively stable (being flexible enough to accommodate advances in disease understanding without major changes), differences in incidence would increasingly reflect true variations in incidence. However, separating true incidence differences from differences resulting from variations in data quality or diagnostic criteria will always require attentive analysis of the data in relation to knowledge of local conditions.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

Acknowledgments

The authors thank Don Ward for help with the English and Chiara Margutti and Samba Sowe for editorial support.

This work was supported by D.G. Sanco Public Health & Consumer Protection (grant agreement no. 2004131) and Compagnia di San Paolo di Torino.

Authorship

Contribution: M.S. was the HAEMACARE project leader and contributed to study design, manuscript writing, and study coordination; C.A. and C.T. carried out the statistical analyses; R.D.A and R.C. gave advice on statistical analyses; C.A., C.T., O.V., R.M.-G., M.M., A.S., J.-M.L., and F.B. interpreted results and contributed to writing the manuscript; and the HAEMACARE Working Group provided the population-based incidence data for hematologic malignancies.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Milena Sant, Department of Preventive and Predictive Medicine, Unit of Analytical Epidemiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, I-20133, Milan, Italy; e-mail: milena.sant@istitutotumori.mi.it.

Appendix: HAEMACARE Working Group

Austria: M. Hackl (National Cancer Registry of Austria); Czech Republic: J. Holub (West Bohemia Cancer Registry); France: M. Maynadie (Côte d'Or Haematological Malignancies Cancer Registry); Germany: B. Holleczek (Saarland Cancer Registry); Iceland: L. Tryggvadottir (National Cancer Registry of Iceland); Ireland: H. Comber (National Cancer Registry of Ireland); Italy: F. Bellù (Alto Adige Cancer Registry), A. Giacomin (Biella Cancer Registry), S. Ferretti (Ferrara Cancer Registry), E. Crocetti (Firenze Cancer Registry), D. Serraino (Friuli Cancer Registry), M. Vercelli (Descriptive Epidemiology Unit, Department of Health Sciences, University of Genoa), M. Federico (Modena Cancer Registry), M. Fusco (Napoli Cancer Registry), M. Michiara (Parma Cancer Registry), R. Tumino (Ragusa Cancer Registry), L. Mangone (Reggio Emilia Cancer Registry), F. Falcini (Romagna Cancer Registry), A. Iannelli (Salerno Cancer Registry), M. Budroni (Sassari Cancer Registry), R. Zanetti (Torino Cancer Registry), S. Piffer (Trento Cancer Registry), F. La Rosa (Umbria Cancer Registry), P. Zambon (Venetian Cancer Registry), M. Sant (Project Leader), C. Allemani, F. Berrino, S. Sowe, C. Tereanu (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan), R. Capocaccia, R. De Angelis, A. Simonetti (National Centre for Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanità, Rome); Malta: K. England (National Cancer Registry of Malta); Norway: F. Langmark (National Cancer Registry of Norway); Poland: J. Rachtan (Cracow Cancer Registry), R. Mezyk (Kielce Cancer Registry), M. Zwierko (Warsaw Cancer Registry); Slovakia: M. Ondrusova (National Cancer Registry of the Slovak Republic); Slovenia: M. Primic-Žakelj (National Cancer Registry of Slovenia); Spain: R. Marcos-Gragera (Girona Cancer Registry); Sweden: S. Khan (National Cancer Registry of Sweden); Switzerland: G. Jundt (Basel Cancer Registry), M. Usel (Geneva Cancer Registry), S. M. Ess (St Gall Cancer Registry), A. Bordoni (Ticino Cancer Registry); The Netherlands: O. Visser (Amsterdam Cancer Registry), R. Otter (CCC-Groningen, North Netherlands), J. W. Coebergh (Eindhoven Cancer Registry), S. Siesling (CCC-Stedendriehoek Twente); UK–England: D. Greenberg (Eastern Cancer Registration and Information Centre), N. Easey (Northern and Yorkshire Cancer Registry), M. Roche (Oxford Cancer Intelligence Unit), G. Lawrence (West-Midlands Cancer Intelligence Unit); UK–Northern Ireland: A. Gavin (Northern Ireland Cancer Registry); UK–Scotland: D. H. Brewster (Scottish Cancer Registry); UK–Wales: J. Steward (Welsh Cancer Intelligence & Surveillance Unit).

References

References
1
Curado
MP
Edwards
B
Shin
HR
Cancer Incidence in Five Continents
2007
, vol. 
Vol. 9.
 
Lyon, France
IARC Press
pg. 
160
 
2
Ferlay
J
Bray
F
Pisani
P
Parkin
DM
GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide IARC CancerBase
2004
Lyon, France
IARC Press
 
No. 5. Version 2.0
3
Carli
PM
Delafosse
P
Duchenet
V
, et al. 
Guide de recommandations pour l'enregistrement des hémopathies malignes par les registres de cancer
2005
Accessed March 28, 2010
Paris, France
INVS and FRANCIM
 
4
Percy
C
Shanmugaratnam
K
Whelan
S
, et al. 
International Classification of Diseases for Oncology (ICD-O)
2000
3rd ed
Geneva, Switzerland
World Health Organization
5
Jaffe
ES
Harris
LN
Stein
H
Vardiman
JW
World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues
2001
Lyon, France
IARC Press
6
Swerdlow
SH
Campo
E
Harris
NL
, et al. 
World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues
2008
Lyon, France
IARC Press
7
HAEMACARE-Cancer Registry Based project on Haematologic Malignancies. Background, rationale and aims.
Accessed March 8, 2010 
8
Accessed March 8, 2010 
9
Morton
LM
Turner
JJ
Cerhan
JR
, et al. 
Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph).
Blood
2007
, vol. 
110
 
2
(pg. 
695
-
708
)
10
De Angelis
R
Francisci
S
Baili
P
, et al. 
The EUROCARE-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis.
Eur J Cancer
2009
, vol. 
45
 
6
(pg. 
909
-
930
)
11
Morton
LM
Wang
SS
Devesa
SS
Hartge
P
Weisenburger
DD
Linet
MS
Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.
Blood
2006
, vol. 
107
 
1
(pg. 
265
-
276
)
12
Rollison
DE
Howlader
N
Smith
MT
, et al. 
Epidemiology of myelodysoplastic syndromes and chronic myeloproliferative disorders in the US, 2001-2004, using data from NAACCR and SEER programs.
Blood
2008
, vol. 
112
 
1
(pg. 
45
-
52
)
13
Coussens
LM
Werb
Z
Inflammation and cancer.
Nature
2002
, vol. 
420
 
6917
(pg. 
860
-
867
)
14
Kim
AS
Eastmond
DA
Preston
RJ
Childhood acute lymphocytic leukemia and perspectives on risk assessment of early-life stage exposures.
Mutat Res
2006
, vol. 
613
 
2
(pg. 
138
-
160
)
15
Ahlbom
A
Day
N
Feychting
M
, et al. 
A pooled analysis of magnetic fields and childhood leukaemia.
Br J Cancer
2000
, vol. 
83
 
5
(pg. 
692
-
698
)
16
Steffen
C
Auclerc
MF
Auvrignon
A
, et al. 
Acute childhood leukaemia and environmental exposure to potential sources of benzene and other hydrocarbons: a case-control study.
Occup Environ Med
2004
, vol. 
61
 
9
(pg. 
773
-
778
)
17
Rudant
J
Menegaux
F
Leverger
G
, et al. 
Childhood hematopoietic malignancies and parental use of tobacco and alcohol: the ESCALE study (SFCE).
Cancer Causes Control
2008
, vol. 
19
 (pg. 
1277
-
1290
)
18
Swerdlow
AJ
Epidemiology of Hodgkin's disease and non-Hodgkin's lymphoma European.
Eur J Nucl Med Mol Imaging
2003
, vol. 
30
 
1 suppl
(pg. 
S3
-
S12
)
19
Cader
FZ
Kearns
P
Young
L
Murray
P
Vockerodt
M
The contribution of the Epstein-Barr virus to the pathogenesis of childhood lymphomas.
Cancer Treat Rev
2010
, vol. 
36
 
4
(pg. 
348
-
353
)
20
Bassil
KL
Vakil
C
Sanborn
M
Cole
DC
Kaur
JS
Kerr
KJ
Cancer health effects of pesticides: systematic review.
Can Fam Physician
2007
, vol. 
53
 (pg. 
1704
-
1711
)
21
Merhi
M
Raynal
H
Cahuzac
E
Vinson
F
Cravedi
JP
Gamet-Payrastre
L
Occupational exposure to pesticides and risk of hematopoietic cancers: meta-analysis of case-control studies.
Cancer Causes Control
2007
, vol. 
18
 
10
(pg. 
1209
-
1226
)
22
Hauptmann
M
Lubin
JH
Stewart
PA
Hayes
RB
Blair
A
Mortality from lymphohematopoietic malignancies among workers in formaldehyde industries.
J Natl Cancer Inst
2003
, vol. 
95
 
21
(pg. 
1615
-
1623
)
23
Pesatori
AC
Consonni
D
Rubagotti
M
Grillo
P
Bertazzi
PA
Cancer incidence in the population exposed to dioxin after the “Seveso accident”: twenty years of follow-up.
Environ Health
2009
, vol. 
8
 pg. 
39
 
24
European Centre for Disease Prevention and Control/WHO Regional Office for Europe.
HIV/AIDS Surveillance in Europe 2008
2009
Stockholm, Sweden
European Centre for Disease Prevention and Control
25
Alexander
DD
Mink
PJ
Adami
HO
, et al. 
The non-Hodgkin lymphomas: a review of the epidemiologic literature.
Int J Cancer
2007
, vol. 
120
 (pg. 
1
-
39
)
26
Marcos Gragera
R
Pollá
M
Chirlaque
MD
Guma
J
Sanchez
MJ
Garau
I
Attenuation of the epidemic increase in non-Hodgkin's lymphomas in Spain.
Ann Oncol
2010
, vol. 
21
 
3
(pg. 
iii90
-
iii96
)
27
Lee
DJ
Voti
L
MacKinnon
J
, et al. 
Gender- and race-specific comparison of tobacco-associated cancer incidence trends in Florida with SEER regional cancer incidence data.
Cancer Causes Control
2008
, vol. 
19
 
7
(pg. 
711
-
723
)
28
Gorini
G
Stagnaro
E
Fontana
V
, et al. 
Alcohol consumption and risk of leukemia: a multi center case-control study.
Leuk Res
2007
, vol. 
31
 
3
(pg. 
379
-
386
)
29
Cook
MB
Dawsey
SM
Freedman
ND
, et al. 
Sex disparities in cancer incidence by period and age.
Cancer Epidemiol Biomarkers Prev
2009
, vol. 
18
 
4
(pg. 
1174
-
1182
)
30
Quaglia
A
Tavilla
A
Shack
L
, et al. 
The cancer survival gap between elderly and middle-aged patients in Europe is widening.
Eur J Cancer
2009
, vol. 
45
 (pg. 
1006
-
1016
)